慢性阻塞性肺疾病稳定期管理的几个新视点：2021版 GOLD指南解读
李庆云, 孙娴雯 . 慢性阻塞性肺疾病稳定期管理的几个新视点：2021版 GOLD指南解读[J]. 诊断学理论与实践, 2021 , 20(01) : 43 -47 . DOI: 10.16150/j.1671-2870.2021.01.006
| [1] | Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease[R/OL]. [2021-02-20]. http://gold-copd.html. |
| [2] | Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study[J]. Lancet, 2018, 391(10131):1706-1717. |
| [3] | Li X, Wu Z, Xue M, et al. Smoking status affects clinical characteristics and disease course of acute exacerbation of chronic obstructive pulmonary disease: a prospectively observational study[J]. Chron Respir Dis, 2020, 17:1479973120916184. |
| [4] | Dransfield MT, Kunisaki KM, Strand MJ, et al. Acute exacerbations and lung function loss in smokers with and without chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2017, 195(3):324-330. |
| [5] | Sonnex K, Alleemudder H, Knaggs R. Impact of smoking status on the efficacy of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review[J]. BMJ Open, 2020, 10(4):e037509. |
| [6] | Bai JW, Chen XX, Liu S, et al. Smoking cessation affects the natural history of COPD[J]. Int J Chron Obstruct Pulmon Dis, 2017, 12:3323-3328. |
| [7] | Layden JE, Ghinai I, Pray I, et al. Pulmonary illness related to e-cigarette use in illinois and wisconsin-final report[J]. N Engl J Med, 2020, 382(10):903-916. |
| [8] | Blount BC, Karwowski MP, Shields PG, et al. Vitamin E acetate in bronchoalveolar-lavage fluid associated with EVALI[J]. N Engl J Med, 2020, 382(8):697-705. |
| [9] | Gotts JE, Jordt SE, McConnell R, et al. What are the respiratory effects of e-cigarettes?[J]. BMJ, 2019, 367:l5980. |
| [10] | Sharma A, Lee J, Fonseca AG, et al. E-cigarettes compromise the gut barrier and trigger inflammation[J]. Science, 2021, 24(2):102035. |
| [11] | Jia X, Zhou S, Luo D, et al. Effect of pharmacist-led interventions on medication adherence and inhalation technique in adult patients with asthma or COPD: a systema-tic review and meta-analysis[J]. J Clin Pharm Ther, 2020, 45(5):904-917. |
| [12] | Willard-Grace R, Chirinos C, Wolf J, et al. Lay health coaching to increase appropriate inhaler Use in COPD: a randomized controlled trial[J]. Ann Fam Med, 2020, 18(1):5-14. |
| [13] | van der Molen T, van Boven JF, Maguire T, et al. Optimizing identification and management of COPD patients- reviewing the role of the community pharmacist[J]. Br J Clin Pharmacol, 2017, 83(1):192-201. |
| [14] | Hesso I, Gebara SN, Kayyali R. Impact of community pharmacists in COPD management: Inhalation technique and medication adherence[J]. Respir Med, 2016, 118:22-30. |
| [15] | Vitacca M, Paneroni M, Zampogna E, et al. High-flow oxygen therapy during exercise training in patients with chronic obstructive pulmonary disease and chronic hypoxemia: a Multicenter randomized controlled trial[J]. Phys Ther, 2020, 100(8):1249-1259. |
| [16] | Rutkowski S, Rutkowska A, Kiper P, et al. Virtual reality rehabilitation in patients with chronic obstructive pulmonary disease: a randomized controlled trial[J]. Int J Chron Obstruct Pulmon Dis, 2020, 15:117-124. |
| [17] | 李庆云. 国外睡眠呼吸疾病家庭无创正压通气治疗指南及专家共识概述[J]. 中华结核和呼吸杂志, 2017, 40(9):660-662. |
| [18] | Wilson ME, Dobler CC, Morrow AS, et al. Association of home noninvasive positive pressure ventilation with clinical outcomes in chronic obstructive pulmonary disease: a systematic review and meta-analysi[J]. JAMA, 2020, 323(5):455-465. |
| [19] | Magdy DM, Metwally A. Effect of average volume-assured pressure support treatment on health-related quality of life in COPD patients with chronic hypercapnic respiratory failure: a randomized trial[J]. Respir Res, 2020, 21(1):64. |
| [20] | Mouronte-Roibás C, Leiro-Fernández V, Fernández-Villar A, et al. COPD, emphysema and the onset of lung cancer. A systematic review[J]. Cancer Lett, 2016, 382(2):240-244. |
| [21] | Sanchez-Salcedo P, Berto J, de-Torres JP, et al. Lung cancer screening: fourteen year experience of the Pamplona early detection program (P-IELCAP)[J]. Arch Bronconeumol, 2015, 51(4):169-176. |
| [22] | Caramori G, Casolari P, Cavallesco GN, et al. Mechanisms involved in lung cancer development in COPD[J]. Int J Biochem Cell Biol, 2011, 43(7):1030-1044. |
| [23] | Houghton AM. Mechanistic links between COPD and lung cancer[J]. Nat Rev Cancer, 2013, 13(4):233-245. |
| [24] | Celli BR. Chronic obstructive pulmonary disease and lung cancer: common pathogenesis, shared clinical challenges[J]. Proc Am Thorac Soc, 2012, 9(2):74-79. |
| [25] | Moyer VA; U.S.Preventive Services Task Force. Scree-ning for lung cancer: U.S. Preventive Services Task Force recommendation statement[J]. Ann Intern Med, 2014, 160(5):330-338. |
| [26] | Ashraf H, Saghir Z, Dirksen A, et al. Smoking habits in the randomised Danish Lung Cancer Screening Trial with low-dose CT: final results after a 5-year screening programme[J]. Thorax, 2014, 69(6):574-579. |
| [27] | Suissa S, Dell'Aniello S, Gonzalez AV, et al. Inhaled corticosteroid use and the incidence of lung cancer in COPD[J]. Eur Respir J, 2020, 55(2):1901720. |
| [28] | Leung JM, Yang CX, Tam A, et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19[J]. Eur Respir J, 2020, 55(5):2000688. |
| [29] | Maes T, Bracke K, Brusselle GG. COVID-19, asthma, and inhaled corticosteroids: another beneficial effect of inhaled corticosteroids?[J]. Am J Respir Crit Care Med, 2020, 202(1):8-10. |
| [30] | Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: prospec-tive observational cohort study[J]. BMJ, 2020, 369:m1985. |
| [31] | Hippisley-Cox J, Young D, Coupland C, et al. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people[J]. Heart, 2020, 106(19):1503-1511. |
| [32] | RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with COVID-19[J]. N Engl J Med, 2021, 384(8):693-704. |
| [33] | World Health Organization. Clinical management of COVID-19[R/OL]. Interim guidance. 2020-05-27[2021-02-20]. https://www.who.int/publications/i/item/clinical-mang ement-of-covid-19. |
| [34] | Dobesh PP, Trujillo TC. Coagulopathy, venous thromboembolism, and anticoagulation in patients with COVID-19[J]. Pharmacotherapy, 2020, 40(11):1130-1151. |
| [35] | Malik P, Patel U, Mehta D, et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis[J]. BMJ Evid Based Med, 2020:bmjebm-2020-111536. |
| [36] | Bellani G, Laffey JG, Pham T, et al. Noninvasive ventilation of patients with acute respiratory distress syndrome. Insights from the LUNG SAFE Study[J]. Am J Respir Crit Care Med, 2017, 195(1):67-77. |
/
| 〈 |
|
〉 |
